Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 62M | 57M | 63M | 81M | 102M |
| Gross Profit | 21M | 19M | 22M | 33M | 49M |
| Operating Income | -21M | -27M | -15M | 4M | 82K |
| EBITDA | -17M | -24M | -17M | 11M | 3M |
| Net Income | -32M | -24M | -41M | 875K | -6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.58
+0.00% today
1Y Change
+5.44%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Trinity Biotech plc (TRIB) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.58 and up 5.4% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +8.3%, EPS growth of +44.8%, a dividend yield of 0.0%. What stands out right now is revenue +8.3%, EPS +44.8%, free cash flow -15.3% with operating margin -40.7% and ROIC -27.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Stock Foundry combines TRIB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRIB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TRIB Max Drawdown
-71.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TRIB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$102.0M
+25.7% YoY
FY Net Income
-$6.4M
-830.1% YoY
Free Cash Flow
$13.6M
+198.2% YoY
Revenue Growth
+8.3%
EPS Growth
+44.8%
Gross Margin
34.7%
Net Margin
-75.9%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 62M | 57M | 63M | 81M | 102M |
| Gross Profit | 21M | 19M | 22M | 33M | 49M |
| Operating Income | -21M | -27M | -15M | 4M | 82K |
| EBITDA | -17M | -24M | -17M | 11M | 3M |
| Net Income | -32M | -24M | -41M | 875K | -6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 4M | 7M | 26M | 27M |
| Total Assets | 103M | 59M | 92M | 119M | 130M |
| Total Liabilities | 138M | 83M | 94M | 119M | 133M |
| Shareholder Equity | -35M | -24M | -2M | -319K | -2M |
| Total Debt | 101M | 67M | 72M | 99M | 104M |
| Net Debt | 96M | 64M | 52M | 73M | 77M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
24M
+79.4% YoY
Capital Expenditures
10M
-17.3% YoY
Free Cash Flow
14M
+198.2% YoY
Key ratios
Gross Margin
34.7%
Operating Margin
-40.7%
Net Margin
-75.9%
ROE
80.7%
Debt / Equity
-2.14x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.